More than 350,000 persons in the U.S. have end-stage renal disease (ESRD), and at least 10-fold more have a significant degree of renal insufficiency (1,2). Cardiovascular disease accounts for more than 50% of deaths among persons with ESRD, and the annual cardiovascular mortality rate is more than an order of magnitude greater than in the non-ESRD population, especially among younger (